These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 17217047)
21. [Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia]. Wang GJ; Li W; Cui JW; Gao SJ; Yao C; Jiang ZY; Song YQ; Yuan CJ; Yang Y; Liu ZL Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1093-6. PubMed ID: 16029564 [TBL] [Abstract][Full Text] [Related]
22. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Dayyani F; Kantarjian H; O'Brien S; Pierce S; Jones D; Faderl S; Garcia-Manero G; Cortes J; Ravandi F Cancer; 2011 Jan; 117(1):110-5. PubMed ID: 20803607 [TBL] [Abstract][Full Text] [Related]
23. Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy. Fang J; Chen SJ; Tong JH; Wang ZG; Chen GQ; Chen Z Cancer Biol Ther; 2002; 1(6):614-20. PubMed ID: 12642682 [TBL] [Abstract][Full Text] [Related]
30. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)]. Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468 [TBL] [Abstract][Full Text] [Related]
31. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα. Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687 [TBL] [Abstract][Full Text] [Related]
32. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Lo-Coco F; Hasan SK Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012 [TBL] [Abstract][Full Text] [Related]
33. Role of arsenic trioxide in acute promyelocytic leukemia. Iland HJ; Seymour JF Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117 [TBL] [Abstract][Full Text] [Related]
35. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia. Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453 [TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Chen L; Wang J; Hu X; Xu X Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286 [TBL] [Abstract][Full Text] [Related]
37. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151 [TBL] [Abstract][Full Text] [Related]
38. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181 [TBL] [Abstract][Full Text] [Related]
39. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia. Calleja EM; Warrell RP Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887 [TBL] [Abstract][Full Text] [Related]
40. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Au WY; Chim CS; Lie AK; Liang R; Kwong YL Br J Haematol; 2002 Apr; 117(1):130-2. PubMed ID: 11918543 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]